Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma

July 17th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.

FDA Places Partial Clinical Hold on Phase 1 Trial of Seclidemstat Plus Azacitidine in MDS/CMML

July 16th 2024

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.

CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration

July 15th 2024

Francisco Hernandez-Ilizaliturri, MD, details factors that influence CAR T-cell therapy selection in relapsed/refractory follicular lymphoma.

FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML

July 15th 2024

The investigational menin-MLL inhibitor DSP-5336 has received FDA fast track designation in KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.

FDA Completes End-of-Phase 2 Meeting for Annamycin Plus Cytarabine in AML

July 15th 2024

Moleculin Biotech completed an end-of-phase 2 meeting with the FDA regarding the investigation of annamycin plus cytarabine in acute myeloid leukemia.

Differentiation Therapy in Acute Myeloid Leukemia: Not Just for APL Anymore

July 15th 2024

Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

July 15th 2024

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

SLS009 Earns EMA Orphan Drug Designation for AML

July 11th 2024

SLS009 has been granted orphan drug designation by the EMA for the treatment of patients with acute myeloid leukemia.

Phillips Discusses Past Progress and Previews the Future in Hematologic Cancers

July 10th 2024

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

HyBryte Continues to Improve mCAILS in Early Cutaneous T-Cell Lymphoma

July 10th 2024

Up to 12 months of treatment with SGX301 produced lesion responses in patients with early-stage cutaneous T-cell lymphoma.

Durable Responses With GLPG5101 Suggest Feasibility of Decentralized CAR T Manufacturing in R/R NHL

July 9th 2024

GLPG5101 produced high CRs in patients with relapsed/refractory non-Hodgkin lymphoma, indicating the feasibility of decentralized CAR T manufacturing.

Remestemcel-L BLA Is Resubmitted for Steroid-Refractory aGVHD

July 9th 2024

The BLA seeking approval for remestemcel-L for children with steroid-refractory acute graft-vs-host-disease has been resubmitted to the FDA.

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study

July 9th 2024

BGB-16673-101 (NCT05006716) is a phase 1 study of a bruton tyrosine kinase degrader (BGB-16673) in patients with relapsed or refractory CLL/SLL.

Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

July 9th 2024

DREAMM-8 (NCT04484623) is an ongoing, randomized, open-label, phase 3 study evaluating BPd vs PVd in patients with RRMM previously treated with ≥1 line of therapy including lenalidomide.

The CSF-1R Signaling Pathway in GVHD and Investigational Agents Targeting this Pathway

July 8th 2024

Dr. Choe discusses the potential role of the CSF-1R signaling pathway in the pathogenesis of numerous diseases, including GVHD. A video segment explores how dysregulation of this pathway can contribute to the development and progression of GVHD, providing the rationale for targeting CSF-1R as a potential therapeutic strategy.

Graft-Versus-Host Disease: Pathogenesis, Clinical Challenges, and Unmet Treatment Needs

July 8th 2024

In this video, Dr. Hannah Choe provides an overview of the background of graft-versus-host disease (GVHD), discusses currently approved treatments and their limitations, and the significant unmet treatment needs in GVHD.

China’s NMPA Approves Selinexor for R/R DLBCL

July 8th 2024

Selinexor has received approval as monotherapy for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in China.

STAT3 Degrader KT-333 is Well Tolerated Across R/R Hematologic Malignancies and Solid Tumors

July 6th 2024

KT-333 was well tolerated in relapsed/refractory hematologic and solid tumor cancers, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.

Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

July 5th 2024

The study assessed the comparative efficacy of zanubrutinib vs acalabrutinib in patients with R/R MCL, in the absence of head-to-head clinical trials, using population-adjusted indirect treatment comparison via simulated treatment comparison approach. Data source for the efficacy of zanubrutinib was informed by the pooled individual patient-level data from 2 clinical trials: BGB-3111-206 (NCT03206970) and BGB-3111-AU-003 (NCT02343120). The efficacy of acalabrutinib was informed by the published aggregated data of the ACE-LY-004 trial (NCT02213926).

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.